We investigated PCT and CRP kinetics in critically ill COVID-19 patients treated with dexamethasone (DEXA) with or without tocilizumab (TOCI), and assessed the value of these biomarkers to detect secondary infections. This evidence concerns the gene CALCA and COVID-19.